Arrowhead Pharmaceuticals (ARWR) announced its public offerings, pricing $625M of 0.00% convertible senior notes due in 2032 and 3.1M shares of common stock at $64.50 per share. Instead of common ...
H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $85 from $80 and keeps a Buy rating on the shares. The firm says the company’s “transformative” fiscal Q4 was driven by FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback